Clopidogrel and Omeprazole: Interaction Details
- Clopidogrel
- Plavix
- Omeprazole
- PrilosecPrilosec OTC
Medically reviewed by Dr. Brian Staiger, PharmD, BCPS
Also reviewed by the HelloPharmacist Editorial Team Updated AI-assisted Details about this page
- Dr. Brian Staiger, PharmD, BCPS, is a clinical pharmacist and pharmacotherapy specialist.
- AI-assisted, written
- AI is used only to summarize verified clinical information, never the open internet.
- Editorial policy
- How we build our interaction pages →
- Our AI policy →
A close look at the Clopidogrel and Omeprazole interaction:
Omeprazole
- Prilosec
- Prilosec OTC
What Happens When You Take Clopidogrel With Omeprazole
What can happen when they are taken together (rated Major)
Reduced clopidogrel active exposure and decreased activity
Interaction Deep Dive
A note from Dr. Brian Staiger If you’re a patient, this deep dive may be too technical, or bore you (or both). Read the plain-language explanation →
Clopidogrel, a , should not be combined with omeprazole, a CYP2C19 , because exposure to the active metabolite of clopidogrel falls and is diminished whether the two drugs are administered together or separated by 12 hours.1011 For patients receiving clopidogrel, it is suggested that a different proton pump inhibitor, one that does not interfere with enzymes such as CYP2C19, be selected in place of omeprazole.12
Available evidence indicates that, relative to omeprazole, pantoprazole, lansoprazole, and dexlansoprazole exert a smaller effect on the antiplatelet activity of clopidogrel,10 and the same holds for rABEprazole when it is given 4 hours after clopidogrel.1 Alternatively, when omeprazole is being used, an antiplatelet agent other than clopidogrel may be considered.11
The Clopidogrel and Omeprazole Interaction, Explained
Clopidogrel (Plavix) helps keep your blood from forming dangerous clots, which protects your heart and brain. But it has to be switched on by your liver before it works. Omeprazole (Prilosec), a common heartburn medicine, blocks the liver enzyme that does this switching.
So when the two are taken together, Plavix may not work as well, even if you take them hours apart. That could raise your risk of a clot, heart attack, or stroke. The good news: there are other heartburn options that work well with Plavix. Please talk with your pharmacist or doctor so they can pick the best fit for you.
Mechanism: Clopidogrel is a requiring -mediated bioactivation. Omeprazole inhibits CYP2C19, reducing active thiol exposure and decreasing P2Y12 . Effect persists with dosing separated by 12 hours.
- Direction: reduced clopidogrel ; potential for increased thrombotic events (stent thrombosis, MI, stroke).
- Onset: rapid. Evidence: established. Severity: major.
- Management: avoid combination. If acid suppression is needed, prefer pantoprazole, lansoprazole, or dexlansoprazole (less effect on clopidogrel activity), or rabeprazole given 4 hours after clopidogrel. Alternatively, consider an antiplatelet other than clopidogrel if omeprazole is required.
See the 13 references behind this explanation ↓
From the HelloPharmacist Pharmacy Team
AI-assisted: written with AI from this pair’s record in our interaction database, and reviewed by the HelloPharmacist pharmacy team. Written .
How we build these pages · How we use AI · Our editorial policy
Why Clopidogrel and Omeprazole Interact
The likely mechanism
of -mediated of clopidogrel
How to Manage the Clopidogrel and Omeprazole Interaction
Care teams usually avoid using these two together. Spacing the doses apart does not fix this interaction. Instead, your team may:
- Switch omeprazole to a different stomach-acid medicine that affects Plavix less, such as pantoprazole, lansoprazole, or dexlansoprazole (or rabeprazole taken 4 hours after Plavix).
- Consider a different if omeprazole is needed.
What you can do: Keep taking your medicines as prescribed, and do not stop Plavix on your own. Tell your pharmacist or doctor if you use omeprazole, including over-the-counter Prilosec, so they can choose the right option for you.
Management is individual — confirm any change with your pharmacist or prescriber.
Questions for Your Pharmacist
- Does my dose of Clopidogrel or Omeprazole need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there another option that avoids this interaction?
Literature Reports
11 reports from the published literature. Each one is headed by the title of the published study it comes from.
What these reports are. Short summaries of published evidence on this combination: clinical studies, case reports and, at times, the FDA prescribing information for one of the drugs. They support this interaction, but it does not rest on them alone. It can also rest on prescribing information not summarized here, or on what is expected from how these two drugs, and others in their drug classes, are known to work.
-
Report 1 · Study title
Prescribing information: KONVOMEP powder for oral suspension, omeprazole sodium bicarbonate powder for oral suspension
A crossover clinical study gave 72 healthy subjects clopidogrel (300 mg loading dose, then 75 mg per day) either alone or together with omeprazole (80 mg taken at the same time as clopidogrel) for 5 days. When the two drugs were given together, exposure to the active of clopidogrel fell by 46% (Day 1) and 42% (Day 5).
A separate crossover study in healthy subjects found a comparable interaction between clopidogrel (300 mg loading dose/75 mg daily maintenance dose) and omeprazole 80 mg daily coadministered for 30 days, with exposure to the clopidogrel active metabolite reduced by 41% to 46% across this period. In a further study, 72 healthy subjects received the same doses of clopidogrel and 80 mg omeprazole, but with the drugs given 12 hours apart; findings were similar, indicating that separating the administration times of clopidogrel and omeprazole does not prevent their interaction.13
-
Report 2 · Study title
Cerebrovascular outcomes with proton pump inhibitors and thienopyridines: a systematic review and meta-analysis
A systematic review and metaanalysis of 22 studies (N=131,714) found that, compared with a thienopyridine (clopidogrel or prasugrel) alone, combined treatment with a proton pump and a thienopyridine significantly increased the risk of stroke (adjusted hazard ratio (HR), 1.3; 95% CI, 1.04 to 1.61; 4 studies) and of composite stroke/MI/cardiovascular death (adjusted HR, 1.23; 95% CI, 1.03 to 1.47; 8 studies). No significant difference was observed for myocardial infarction (7 studies), cardiovascular death (6 studies), or all-cause mortality (8 studies). Within the studies, patients were followed for 6 to 30 months (median, 12 months).4
-
Report 3 · Study title
Prescribing information: PLAVIX oral tablets, clopidogrel bisulfate oral tablets
Dedicated drug-drug interaction studies showed that, after multiple doses of clopidogrel 75 mg, use of a proton pump (dexlansoprazole 60 mg, lansoprazole 30 mg, pantoprazole 80 mg, and omeprazole 80 mg) significantly lowered the of the clopidogrel active compared with clopidogrel alone. The largest reduction in clopidogrel metabolite AUC occurred with omeprazole, and the smallest reduction was associated with dexlansoprazole.10
-
Report 4 · Study title
Influence of low-dose proton pump inhibitors administered concomitantly or separately on the anti-platelet function of clopidogrel
In a study of healthy Japanese subjects with differing genotypes (N=41), clopidogrel 75 mg and omeprazole 10 mg (given together in the morning or 12 hours apart in the evening) significantly reduced mean of aggregation relative to clopidogrel alone (47.2% vs 56%), as measured 4 hours after the final clopidogrel dose on day 7. Esomeprazole, lansoprazole, and RABEprazole produced a similar significant reduction when given together in the morning or separately in the evening. However, when clopidogrel was taken after breakfast and RABEprazole after lunch (4 hours after or 20 hours before clopidogrel), the reduction in inhibition of platelet aggregation was not significant.1
-
Report 5 · Study title
Drug interaction between clopidogrel and ranitidine or omeprazole in stable coronary artery disease: a double-blind, double dummy, randomized study
Among patients with coronary artery disease, adding omeprazole significantly reduced the of aggregation (IPA) of clopidogrel (n=41; clopidogrel, 26.3%; combination therapy, 17.4%), whereas adding raNITIdine did not significantly change it (n=44; 32.6%; combination therapy, 30.1%). Every patient took aspirin 100 mg daily before and throughout the study and underwent a baseline IPA measurement (0% for each group).
Patients next received clopidogrel 75 mg daily for one week before the second IPA measurement (time 1), and were then randomized to combination therapy with clopidogrel plus either omeprazole 20 mg twice daily or raNITIdine 150 mg twice daily for one week before the following IPA measurement (time 2). The groups did not differ significantly at either time 1 or time 2. When patients homozygous for the 2C19*2 (loss-of-function) genotype were excluded, the groups differed significantly at time 2.2
-
Report 6 · Study title
Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies
In 3 randomized, placebo-controlled, crossover studies in healthy subjects, coadministering clopidogrel and omeprazole significantly decreased the and of the clopidogrel active (H4) and, as a result, reduced aggregation . Relative to clopidogrel given alone, of clopidogrel (300-mg loading dose; 75 mg/day maintenance dose) with omeprazole (80 mg/day; study 1; n=64) decreased H4 Cmax and AUC by 46% and 45%, respectively, on day 1, and by 42% and 40%, respectively, on day 5.
These decreases in H4 Cmax and AUC corresponded to a reduction in mean inhibition of platelet aggregation (IPA) of 39% on day 1 and 21% on day 5. Similar results were obtained when clopidogrel and omeprazole were given 12 hours apart at the same doses (study 2; n=66) and when the clopidogrel loading and maintenance doses were doubled (study 3; n=62). In a fourth study (n=56), replacing omeprazole with pantoprazole 80 mg/day coadministered with clopidogrel (300-mg loading dose; 75 mg/day maintenance dose) produced a smaller but still significant decrease in H4 Cmax and AUC of 24% and 20%, respectively, on day 1, and 28% and 14%, respectively, on day 5 relative to clopidogrel given alone.3
-
Report 7 · Study title
Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study
A prospective study found significantly better response with clopidogrel 150 mg used concomitantly with pantoprazole than with omeprazole when platelet reactivity was evaluated by the platelet reactivity index-vasoactive stimulated phosphoprotein (PRI-VASP), but not when evaluated by adenosine diphosphate-induced aggregation (ADP-Ag), suggesting that the omeprazole-clopidogrel interaction may not reflect a proton-pump class effect. PRI-VASP precisely measures platelet activation/inactivation through phosphorylation of the P2Y12 receptor, whereas ADP-Ag is not specific solely to the P2Y12 receptor.
In this study, patients who had undergone successful stenting for non-ST segment acute coronary syndrome were discharged on aspirin 75 mg and clopidogrel 150 mg daily and then randomized (1:1) to pantoprazole or omeprazole 20 mg/day. At 1 month, the pantoprazole arm showed significantly better platelet response (less aggregation) to clopidogrel than the omeprazole arm by PRI-VASP (36% +/- 20% vs 48% +/- 17%).
However, platelet response measured by ADP-Ag did not differ significantly between the pantoprazole and omeprazole groups (50 +/- 18% vs 52 +/- 15%, respectively). Nonresponders were significantly fewer with pantoprazole than with omeprazole (23% vs 44%; odds ratio, 2.6; 95% CI, 1.2 to 6.2), emphasizing preferential choice of pantoprazole over omeprazole for clopidogrel-treated patients.5
-
Report 8
The Clopidogrel Medco Outcomes Study of 16,690 coronary-stent patients adherent to clopidogrel found that of clopidogrel with a proton pump (PPI) was associated with a significantly greater incidence and risk of major adverse cardiovascular events (MACE; a composite of myocardial infarction, unstable angina, transient ischemic attack/stroke, coronary revascularization, or cardiovascular death) than no PPI therapy. Overall, patients taking any PPI had a significantly higher risk of MACE (n=6828; 25.1%) than those not receiving PPI therapy (n=9862; 17.9%), with an adjusted hazard ratio (HR) of 1.51 (95% confidence interval (CI), 1.39 to 1.64).
At 1-year follow-up, every PPI was associated with a significant increase in MACE relative to no PPI therapy: pantoprazole (n=1653; 29.2% vs 17.9%; HR, 1.61; 95% CI, 1.41 to 1.88); esomeprazole (n=3257; 24.9% vs 17.9%; HR, 1.57; 95% CI, 1.4 to 1.76); omeprazole (n=2307; 25.1% vs 17.9%; HR, 1.39; 95% CI, 1.22 to 1.57); and lansoprazole (n=785; 24.3% vs 17.9%; HR, 1.39; 95% CI, 1.16 to 1.67). Findings for RABEprazole (n=298) were inconclusive because of limited power and sample size. Additional study is needed to establish whether RABEprazole or dexlansoprazole reduces clopidogrel when coadministered.6
-
Report 9 · Study title
Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome
A retrospective cohort study of Veterans Health Administration patients with acute myocardial infarction or unstable angina (n=8205) found that of clopidogrel and proton pump (PPI), including omeprazole, was associated with a higher risk of death or rehospitalization for acute coronary syndrome (ACS). The study reviewed patients discharged between October 1, 2003 and January 31, 2006 with clopidogrel prescriptions (based on pharmacy refill data).
The odds ratio (OR) of adverse outcomes with clopidogrel and omeprazole (n=3132) was 1.24 (95% confidence interval (CI), 1.08 to 1.41). The primary endpoint of death and rehospitalization for ACS occurred in 29.8% of patients who took both clopidogrel and a PPI at any time during follow-up (n=5244) compared with 20.8% of patients who took clopidogrel without a PPI (n=2961) (OR, 1.25; 95% confidence interval (CI), 1.11 to 1.41); rehospitalization for ACS occurred in 14.6% vs 6.9% (OR, 1.86; 95% CI, 1.57 to 2.20), revascularization procedures in 15.5% vs 11.9% (OR, 1.49; 95% CI, 1.3 to 1.71), and death from all causes in 19.9% vs 16.6% (OR, 0.91; 95% CI, 0.8 to 1.05) of patients, respectively.
Among PPIs prescribed at discharge, 59.7% were omeprazole, 2.9% RABEprazole, 0.4% lansoprazole, 0.2% pantoprazole, and 36.7% more than one type of PPI. PPI use without clopidogrel was not associated with death or rehospitalization for ACS (OR, 0.98; 95% CI, 0.85 to 1.13).7
-
Report 10 · Study title
A population-based study of the drug interaction between proton pump inhibitors and clopidogrel
A population-based nested case-control study (n=2791) in Canada found that, among elderly patients treated for acute MI, treatment with clopidogrel and proton pump (PPI) other than pantoprazole was associated with a higher risk of recurrent myocardial infarction (MI). Across a 69-month study period, patients who died or experienced recurrent MI within 90 days of hospital discharge (n=734) were matched with controls (n=2057) from a cohort of elderly patients (median age, 76 years) discharged on clopidogrel after treatment for acute MI.
Relative to non-PPI users, the higher incidence of recurrent MI within 90 days was associated with concurrent clopidogrel therapy and current PPI use (within 30 days of the discharge date (index date)) (odds ratio (OR), 1.27; 95% confidence interval (CI) 1.03 to 1.57), but not with earlier PPI use (31 to 90 days before the index date) or remote PPI use (91 to 180 days before the index date). Recurrent MI was not associated with use of histamine-2 receptor , use of pantoprazole, or patients not treated with clopidogrel. In contrast, use of PPI (other than pantoprazole) was associated with a significantly increased risk of recurrent MI (OR, 1.4; 95% CI, 1.1 to 1.77).8
-
Report 11 · Study title
Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors
A retrospective, claims-based analysis of medical and pharmacy databases examining acute myocardial infarction (MI) rates among members receiving clopidogrel with or without concurrent proton pump (PPI) therapy showed a 1-year acute MI rate of 1.38% in the control group (no PPI exposure), 3.08% (low PPI exposure based on adherence rate), and 5.03% (high PPI exposure). Using the control group MI incidence as the expected MI rate, the difference in MI rates between the control and high exposure groups was significant.
The analysis also identified small but significant comorbidity differences between groups, with the high exposure group including more patients with preexisting hypertension, diabetes, and greater overall severity of illness at clopidogrel initiation. After adjustment for comorbidity differences, the differences in acute MI rates remained significant: 2.6% (95% confidence interval (CI), 1.01 to 4.19) of the control group experienced MI events compared with 11.38% (95% CI, 8.69 to 14.07) of the high PPI exposure group.9
Clopidogrel and Omeprazole: Common Questions
How serious is the Clopidogrel and Omeprazole interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How is the Clopidogrel and Omeprazole interaction managed?
Care teams usually avoid using these two together. Spacing the doses apart does not fix this interaction. Instead, your team may: Switch omeprazole to a different stomach-acid medicine that affects Plavix less, such as pantoprazole, lansoprazole, or dexlansoprazole (or rabeprazole taken 4 hours after Plavix). Consider a different if omeprazole is needed. What you can do: Keep taking… Management is individual — always follow your own care team's guidance.
How far apart should I take Clopidogrel and Omeprazole?
The interaction record says to take clopidogrel and omeprazole 12 hours apart.
Your pharmacist can help you fit this into the times you take your other medicines.
Is there an alternative to taking Clopidogrel with Omeprazole?
Instead, your team may: Switch omeprazole to a different stomach-acid medicine that affects Plavix less, such as pantoprazole, lansoprazole, or dexlansoprazole (or rabeprazole taken 4 hours after Plavix).
Only your prescriber can decide whether a change fits you, so talk with them before changing either medicine.
How quickly could this interaction happen?
The documented onset is "rapid". Effects can appear quickly, often within about 24 hours of combining the drugs.
How strong is the evidence for this interaction?
The evidence is graded "established". Well documented — supported by controlled studies or strong clinical data.
Ask About the Clopidogrel and Omeprazole Interaction
Ask in your own words about taking Clopidogrel and Omeprazole together. The answer comes from this page’s interaction record and both drugs’ own information.
This box answers questions about this one combination only. For anything else about either drug, open its drug information page or ask a pharmacist.
AI answers from this page’s record and both drugs’ information, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.
References (13)
- Furuta T, Sugimoto M, Kodaira C, et al: Influence of low-dose proton pump inhibitors administered concomitantly or separately on the anti-platelet function of clopidogrel. J Thromb Thrombolysis 2017; 43(3):333-342. PubMed
- Furtado RH, Giugliano RP, Strunz CM, et al: Drug interaction between clopidogrel and ranitidine or omeprazole in stable coronary artery disease: a double-blind, double dummy, randomized study. Am J Cardiovasc Drugs 2016; 16(4):275-284. PubMed
- Angiolillo DJ, Gibson CM, Cheng S, et al: Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. Clin Pharmacol Ther 2011; 89(1):65-74. DOI
- Malhotra K, Katsanos AH, Bilal M, et al: Cerebrovascular outcomes with proton pump inhibitors and thienopyridines: a systematic review and meta-analysis. Stroke 2018; 49(2):312-318. PubMed
- Cuisset T, Frere C, Quilici J, et al: Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study. J Am Coll Cardiol 2009; 54(13):1149-1153.
- The Society for Cardiovascular Angiography and Interventions: A National Study of the Effect of Individual Proton Pump Inhibitors on Cardiovascular Outcomes in Patients Treated with Clopidogrel Following Coronary Stenting: The Clopidogrel Medco Outcomes Study. The Society for Cardiovascular Angiography and Interventions. Washington, DC. 2009.
- Ho PM, Maddox TM, Wang L, et al: Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009; 301(9):937-944. PubMed
- Juurlink DN, Gomes T, Ko DT, et al: A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009; E Pub:1-. DOI
- Pezalla E, Day D, & Pulliadath I: Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors. J Am Coll Cardiol 2008; 52(12):1038-1039. PubMed
- Product Information: PLAVIX® oral tablets, clopidogrel bisulfate oral tablets. sanofi-aventis US LLC (per DailyMed), Morristown, NJ, 2025. DailyMed
- Product Information: PRILOSEC® oral delayed-release suspension, omeprazole magnesium oral delayed-release suspension. Covis Pharma (per DailyMed), Berkeley Heights, NJ, 2024. DailyMed
- Abrignani MG, Gatta L, Gabrielli D, et al: Gastroprotection in patients on antiplatelet and/or anticoagulant therapy: a position paper of National Association of Hospital Cardiologists (ANMCO) and the Italian Association of Hospital Gastroenterologists and Endoscopists (AIGO). Eur J Intern Med 2021; 85:1-13. PubMed
- Product Information: KONVOMEP(TM) powder for oral suspension, omeprazole sodium bicarbonate powder for oral suspension. Azurity Pharmaceuticals Inc (per manufacturer), Woburn, MA, 2022. DailyMed
Other Serious Interactions of Clopidogrel and Omeprazole
Also serious with Clopidogrel
- AbrocitinibContraindicated
- Defibrotide InjectionContraindicated
- Acetaminophen and CodeineMajor
- SertralineMajor
Also serious with Omeprazole
These Medications Also Interact With Supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
With Clopidogrel
- GrapefruitMajor
- St. John's WortMajor
- Activated CharcoalMajor
- PiracetamMajor
- Vitamin EModerate
- SeleniumModerate
- GingerModerate
- TurmericModerate
- + 309 more
With Omeprazole
- GrapefruitMajor
- St. John's WortMajor
- Activated CharcoalMajor
- Vitamin EModerate
- GingerModerate
- TurmericModerate
- Green TeaModerate
- Black PepperModerate
- + 171 more
Check everything you take with our drug–supplement interaction checker.
Still Have Questions About This Combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
About This Library
Built in-house, documented one interaction at a time. Our interaction database is not a complete list of every known interaction: a combination that isn't listed here hasn't been documented by us yet, which never means it's safe. Checking everything you take at once? Ask your pharmacist to review your full medication list. How we build and review it →
What Each Rating Means
Severity Levels
- Contraindicated These should generally not be used together.
- Major Potentially serious — often needs a change or close monitoring. This interaction.
- Moderate Can be significant — usually manageable with monitoring.
- Minor Usually limited clinical impact.
Evidence Grades
- EstablishedWell documented — supported by controlled studies or strong clinical data. This interaction.
- ProbableGood supporting evidence, though not definitively proven.
- SuspectedSome evidence suggests this interaction, but it is not well established.
- PossibleLimited or conflicting evidence; the interaction may occur.
- TheoreticalExpected from how the drugs work, or from studies of similar drugs; this exact pair has little direct study.
How Soon It Shows
- RapidEffects can appear quickly, often within about 24 hours of combining the drugs. This interaction.
- DelayedEffects tend to build up gradually over days to weeks.
- UnspecifiedThe timing of this interaction is not well characterized.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.